Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | NOS2 | P35228 | 9/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050296 | 0.87 | SLC6A4 (0.49) | SLC6A4NOS2SLC6A9CYP2D6SLC6A2 | |
| SCHEMBL6050292 | 0.80 | SLC6A4 (0.45) | SLC6A4NOS2CYP2D6SLC6A2AR | |
| SCHEMBL6050374 | 0.80 | NOS2 (0.54) | SLC6A4NOS2CYP2D6SLC6A2AR | |
| SCHEMBL25413049 | 0.80 | NOS2 (0.54) | SLC6A4NOS2CYP2D6SLC6A2AR | |
| SCHEMBL6050234 | 0.80 | NOS2 (0.54) | SLC6A4NOS2CYP2D6SLC6A2AR | |
| SCHEMBL6050315 | 0.80 | SLC6A4 (0.50) | SLC6A4NOS2CYP2D6SLC6A2AR | |
| SCHEMBL6050500 | 0.80 | SLC6A4 (0.62) | SLC6A4NOS2CYP2D6SLC6A2HRH3 | |
| SCHEMBL6898375 | 0.80 | NOS2 (0.50) | SLC6A4NOS2CYP2D6SLC6A2HRH3 | |
| SCHEMBL6050411 | 0.80 | NOS2 (0.50) | SLC6A4NOS2CYP2D6SLC6A2HRH3 | |
| Hydrochloric Acid SCHEMBL6050403 | 0.79 | SLC6A4 (0.63) | SLC6A4NOS2CYP2D6SLC6A2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414802-B1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | EP | claimed |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | claimed |
| EP-1414802-B1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | EP | disclosed |
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176422-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS1, NOS2 | SLC6A4 1799/4885NOS2 3/4885SLC6A9 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.